Cure My Disease

Don't miss your cure!

 Log in / Sign up

TikTok meets oncology: can influencer videos boost chemo adherence in teens?

NCT ID NCT07724652

Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests whether a social media campaign, co-created with young adult cancer survivors who are also online influencers, can improve how consistently adolescents and young adults (ages 15–25) with acute lymphoblastic leukemia take their daily oral chemotherapy. Participants receive access to an educational website and a series of social media messages designed to build medication self-management skills, confidence, and peer support. The study measures adherence using electronic pill bottle caps that record every dose opening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a social media intervention (#AYAOSM) plus an educational website, designed to improve oral chemotherapy adherence
What this could lead to
If it works, this could offer a low-cost, scalable way to help young cancer patients take their daily chemotherapy as prescribed, potentially improving treatment outcomes.
What could go wrong
This is a behavioral intervention, not a drug — its impact depends on engagement, which may fade over time. The trial is also relatively small and focused on one cancer type, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 15-25 years old * Diagnosed with acute lymphoblastic leukemia (ALL) * Taking 6-mercpatopurine (6-MP) as part of their maintenance treatment with at least 6-months remaining * Be able to speak and read English * Have at least one active social media account (e.g., Instagram, TikTok) or be willing to download a platform for the study * Endorse missing a 6-MP dose in the prior month and/or at least one adherence barrier. Exclusion Criteria: * Cognitive impairments that would limit ability to complete measures, determined by the medical team * Absence of inclusion criteria above.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute lymphobkastic leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia leukemia Medication Adherence neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute lymphobkastic leukemia Medication adherence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.